Ethics and the Business of BioscienceStanford University Press, 2004 - 534 páginas Businesses that produce bioscience products gene tests and therapies, pharmaceuticals, vaccines, and medical devices are regularly confronted with ethical issues concerning these technologies. Conflicts exist between those who support advancements in bioscience and those who fear the consequences of unfettered scientific license. As the debate surrounding bioscience grows, it will be increasingly important for business managers to consider the larger consequences of their work. This groundbreaking book follows industry research, development, and marketing of medical and bioscience products across a variety of fields, including biotechnology, pharmaceuticals, and bio-agriculture. Compelling and current case studies highlight the ethical decisions business managers frequently face. With the increasing visibility and public expectation placed on businesses in this sector, managers need to understand the ethical and social issues. This book addresses that need and provides a framework for incorporating ethical analysis in business decision making. |
Índice
Acknowledgments | xi |
Introduction 3 | xviii |
4 | xviii |
Benefits of addressing ethical and social issues | 13 |
Ethics and Business Activity 233 | 25 |
Moral systems | 31 |
Kantian ethics rights and duties | 39 |
Justice and fairness | 46 |
IndustrySponsored Clinical Research and the Use of Placebo Controls | 195 |
Changing views on placebo controls | 202 |
8 | 227 |
Mitigation of Harm to Subjects Injured in Clinical Research | 235 |
Industry research practice | 242 |
HIV transmission trial in Uganda | 282 |
VaxGen Inc fighting the AIDS epidemic | 288 |
ΙΟ | 329 |
Compensatory justice | 55 |
3 | 65 |
Analysis of case study | 84 |
Rights analysis | 94 |
Ethical reasoning conclusions ΙΟΙ | 101 |
Research Ethics | 106 |
Animal research | 119 |
Industry Regulation and the Product Approval Process | 129 |
Clinical trials process | 137 |
Medical device regulation | 143 |
6 | 151 |
Changes in industryacademic relationships | 159 |
Myriad and OncorMed and the marketing of | 337 |
II | 363 |
Access to Medical Products | 377 |
Accelerated drug approval | 384 |
Mercks U S managed distribution program for | 391 |
12 | 414 |
Advertising Prescription Drugs Directly to Patients | 427 |
DTC prescription drug advertising expenditures | 434 |
Zenecas directtoconsumer advertising | 443 |
519 | |
Otras ediciones - Ver todo
Términos y frases comunes
action activists Adiana AIDS vaccine American analysis animal approval Available benefits bioscience biotechnology BRCA BRCA1 breast cancer business ethics clinical trials conduct considered consumers corporate costs Crixivan dairy decision Declaration of Helsinki developed device disease DTC advertising efficacy ethical and social faculty federal funding gene genetic testing genomics Genzyme Geron groups guidelines harm human subjects industry infection injury involved issues Journal justice laws managers medical product Medicine Merck milk million Monsanto moral mutations Myriad NADII Nolvadex Novartis OncorMed ovarian cancer Parkinson disease patients percent pharmaceutical companies physicians placebo control Posilac potential prescription drug prevent principles problems question rbST rbST-free labels rbST-treated cows reason regulations regulatory risk safety scientific scientists Sect stem cells sterilization tamoxifen therapy tion tissue treated treatment tubal ligation University utilitarian vaccine VaxGen women Zeneca